RIB-ELLE: Ribociclib plus aromatase inhibitor/fulvestrant in HR+, HER2-advanced breast cancer in the real-world Swiss population: 1st interim analysis

R. Popescu, N. Gutierres-Demierre, D. Thorn,C. J. Ackermann,P. Bohanes, A. Chouiter-Djebaili,A. Schreiber, K. Steuer, V. Membrez, M. Kouros, K. Huss-Mischler, K. Zeidler, C. U. Nussbaum,E. Fuhrmann,A. Pedrazzini, K. Weyermann, D. Cavanna, N. Pasche, D. Bottinelli

SWISS MEDICAL WEEKLY（2022）

Cited 0|Views6

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined